Skip to main content
Clinical Trials/NCT04050423
NCT04050423
Recruiting
Not Applicable

Investigation of Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses

Sunnybrook Health Sciences Centre1 site in 1 country1,200 target enrollmentSeptember 23, 2014
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Sunnybrook Health Sciences Centre
Enrollment
1200
Locations
1
Primary Endpoint
Select the best quantitative ultrasound parameters that can facilitate breast cancer characterization, non-invasively
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Our objective in this study is to identify an optimal set of quantitative ultrasound parameters that can be used, non-invasively, to characterize breast masses with high accuracy, as determined histopathologically. Breast cancer is the most frequent form of non-epithelial cancer diagnosed in women, with approximately 1.5 million new cases diagnosed annually worldwide. Accurate diagnosis and characterization of disease play an important role in therapy planning for breast cancer treatment. Currently, the gold standard method of tumour diagnosis is pathological examination of core biopsy specimens. However, the invasive core biopsies can cause post-surgical complications. Besides, some lesions require repeat biopsy due to sampling errors during the initial biopsy. Also X-ray mammography and ultrasound B-mode images, which are used by radiologists for breast examination, lack reliable information about micro-structural properties of tissues. There is an urgent need of a non-invasive imaging modality that can provide rapid and quantitative information for breast tumour characterization, in real time and at the patient bed. The main goal, as described above, is to select the best quantitative ultrasound parameters that can facilitate breast cancer characterization, non-invasively.

Detailed Description

This project is an observational/early validation study in human subjects that will use ultrasound imaging and spectroscopy to characterize suspected breast cancers. Patients will be imaged with ultrasound, and the acquired data will be analyzed using quantitative ultrasound techniques, in conjunction with textural analysis on generated parametric images. Results of quantitative ultrasound data analysis for these breast lumps will be compared to and correlated with their histopathological characteristics from pathology reports on core biopsy specimens, surgery reports, or radiology reports, available from patient charts. From this data we will potentially estimate the best hybrid ultrasound-based biomarker that can characterize suspected breast cancers, noninvasively.

Registry
clinicaltrials.gov
Start Date
September 23, 2014
End Date
September 2029
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Gregory Czarnota

Radiation Oncologist and Clinician Scientist

Sunnybrook Health Sciences Centre

Eligibility Criteria

Inclusion Criteria

  • Women or men with suspected breast cancer
  • Patients should have the ability to understand and the willingness to sign a written Informed consent document.

Exclusion Criteria

  • Patients who have had chemotherapy, radiotherapy, or major surgery within 4 weeks prior to registering in the study or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to registration
  • Receiving any other investigational agents
  • Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.

Outcomes

Primary Outcomes

Select the best quantitative ultrasound parameters that can facilitate breast cancer characterization, non-invasively

Time Frame: Up to 5 years

Correlate quantitative ultrasound parameters obtained using spectroscopic techniques, in conjunction with textural analysis on generated parametric images, to the histopathological characteristics from pathology reports on core biopsy specimens, surgery reports, or radiology reports.

Secondary Outcomes

  • Results of ultrasound-based breast cancer characterization and clinical outcomes.(Up to 5 years)

Study Sites (1)

Loading locations...

Similar Trials